0001493152-24-026639.txt : 20240709 0001493152-24-026639.hdr.sgml : 20240709 20240709163012 ACCESSION NUMBER: 0001493152-24-026639 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240709 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240709 DATE AS OF CHANGE: 20240709 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41463 FILM NUMBER: 241107756 BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 8-K 1 form8-k.htm
false 0001712762 0001712762 2024-07-09 2024-07-09 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2024-07-09 2024-07-09 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2024-07-09 2024-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

July 9, 2024

Date of Report (Date of earliest event reported)

 

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

22211 W Interstate 10

Suite 1206

San Antonio, Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On July 9, 2024, bioAffinity Technologies, Inc. (the “Company”) issued a press release that included financial information for its fiscal quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 8.01. Other Events

 

On July 9, 2024, the Company issued a press release that included financial information for its fiscal quarter ended June 30, 2024, which included a reported 217% growth in second-quarter sales over first quarter 2024 and 53 CyPath® Lung tests ordered by physicians in the first quarter of 2024 compared to 168 CyPath® Lung tests ordered by physicians in the second quarter of 2024 .

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is furnished with this Current Report on Form 8-K:

 

Exhibit   Description
99.1   Press Release issued by bioAffinity Technologies, Inc. dated July 9, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  bioAffinity Technologies, Inc.
   
  By: /s/ Maria Zannes
    Maria Zannes
    President and Chief Executive Officer

 

Dated: July 9, 2024

 

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

 

Sales of CyPath® Lung tests continue to accelerate as sales team expands

customer base of pulmonology practices

 

SAN ANTONIO, TX (July 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today raised its full-year forecast for sales of CyPath® Lung in the Company’s test marketing program by 85% and reported 217% growth in second-quarter sales over first quarter 2024, outpacing the forecast previously reported in May by 75%.

 

CyPath® Lung fulfills the need for a noninvasive test for the early detection of lung cancer and is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule. The lung cancer diagnostics market is projected to reach $4.7 billion by 2030, according to ReportLinker’s industry analysis.

 

The accelerating growth of CyPath® Lung sales builds on the foundation laid in 2023 when bioAffinity launched a strategic beta marketing program in Texas after obtaining a CPT code and Medicare reimbursement for CyPath® Lung. This initiative included hiring seasoned sales executives to educate physicians on the benefits of CyPath® Lung for patients at risk for lung cancer. Additionally, private insurers have begun reimbursing for the test, which is billed at $1,900 by Precision Pathology Laboratory Services (PPLS), a wholly owned subsidiary of bioAffinity. PPLS is projected to generate between $9.2 and $9.6 million revenue in 2024, including sales of CyPath® Lung.

 

“We strategically focused our marketing efforts on our home state of Texas as we launched CyPath® Lung, a noninvasive test that has shown 92% sensitivity and 87% specificity in detecting cancer in the lung for people who have pulmonary nodules 20 millimeters or less,” bioAffinity Technologies President and CEO Maria Zannes said. “The strategic decision to begin our commercial launch in Texas allows us to hone our message, improve operations and prepare for a broader market launch now scheduled for the fourth quarter of 2024.”

 

In the second quarter of 2024, physicians ordered 168 CyPath® Lung tests. Based on the accelerating pace of test orders, the Company has raised its forecast for 2024 CyPath® Lung sales to exceed 880 tests. “In the fourth quarter of 2023, we processed 12 CyPath® Lung tests. That number increased to 53 tests in the first quarter of 2024 and now 168 tests in the second quarter,” Ms. Zannes said.

 

 

 

 

Texas represents the third largest market of critical care pulmonologists in the nation, according to a November 2023 market insight report by IQVIA Holdings Inc., a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. bioAffinity estimates Texas physicians currently using CyPath® Lung for their patients at high risk for lung cancer represent 10% of the Texas critical care pulmonology market, and the expanded sales team is onboarding new physicians weekly. Physicians in eight other states are ordering CyPath® Lung after referrals from their peers who have incorporated the test into their clinical practice, including pulmonologists in New Jersey, Ohio, Pennsylvania, Michigan, North Carolina, California, Florida and Arizona.

 

In addition to critical care pulmonologists who are considered opinion leaders in advancing innovative lung cancer diagnostics like CyPath® Lung, other physician specialties that may use the test for their high-risk patients include general pulmonologists and primary care physicians.

 

“Lung cancer screening and early diagnosis improve outcomes and extend lives for patients at high risk for lung cancer. But imaging is not always definitive, especially for pulmonary nodules smaller than 20 millimeters,” Ms. Zannes said. “By combining the simplicity of sputum as a biological sample with advanced flow cytometry and automated analysis, CyPath® Lung gives physicians a valuable diagnostic tool with high sensitivity and specificity for high-risk patients, especially those with indeterminate nodules. And their patients appreciate the user-friendly, noninvasive design of the test.”

 

About CyPath® Lung

 

CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.

 

About bioAffinity Technologies, Inc.

 

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.

 

 

 

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding raising the full-year forecast for sales of CyPath® Lung, PPLS generating between $9.2 and $9.6 million in revenue in 2024 including sales of CyPath® Lung, honing the Company’s message, improving operations and preparing for a broader CyPath® Lung market launch for the fourth quarter of 2024, 2024 CyPath® Lung sales exceeding 880 tests, Texas physicians currently using CyPath® Lung for their patients at high risk for lung cancer representing 10% of the Texas critical care pulmonology market, the sales team onboarding new physicians weekly, other physician specialties using the CyPath® Lung test for their high-risk patients and the lung cancer diagnostics market reaching $4.7 billion by 2030. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to accelerate the commercialization of CyPath® Lung and capitalize on the lung cancer diagnostics market; the ability of CyPath® Lung to provide the anticipated benefits to patients and physicians; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

Contacts

bioAffinity Technologies

Julie Anne Overton

Director of Communications

jao@bioaffinitytech.com

 

Investor Relations

Dave Gentry

RedChip Companies Inc.

1-800-RED-CHIP (733-2447) or 407-491-4498

BIAF@redchip.com

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end GRAPHIC 4 ex99-1_002.jpg begin 644 ex99-1_002.jpg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end EX-101.SCH 5 biaf-20240709.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 biaf-20240709_def.xml XBRL DEFINITION FILE EX-101.LAB 7 biaf-20240709_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.007 per share Tradeable Warrants to purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 biaf-20240709_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 09, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 09, 2024
Entity File Number 001-41463
Entity Registrant Name bioAffinity Technologies, Inc.
Entity Central Index Key 0001712762
Entity Tax Identification Number 46-5211056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22211 W Interstate 10
Entity Address, Address Line Two Suite 1206
Entity Address, City or Town San Antonio
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78257
City Area Code (210)
Local Phone Number 698-5334
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $0.007 per share  
Title of 12(b) Security Common Stock, par value $0.007 per share
Trading Symbol BIAF
Security Exchange Name NASDAQ
Tradeable Warrants to purchase Common Stock  
Title of 12(b) Security Tradeable Warrants to purchase Common Stock
Trading Symbol BIAFW
Security Exchange Name NASDAQ
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioaffinitytech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports biaf-20240709.xsd biaf-20240709_def.xml biaf-20240709_lab.xml biaf-20240709_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BIAF", "nsuri": "http://bioaffinitytech.com/20240709", "dts": { "schema": { "local": [ "biaf-20240709.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "biaf-20240709_def.xml" ] }, "labelLink": { "local": [ "biaf-20240709_lab.xml" ] }, "presentationLink": { "local": [ "biaf-20240709_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 27 }, "report": { "R1": { "role": "http://bioaffinitytech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "auth_ref": [] }, "BIAF_CommonStockParValue0.007PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20240709", "localname": "CommonStockParValue0.007PerShareMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.007 per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "BIAF_TradeableWarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20240709", "localname": "TradeableWarrantsToPurchaseCommonStockMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Tradeable Warrants to purchase Common Stock" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001493152-24-026639-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-026639-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001712762 2024-07-09 2024-07-09 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2024-07-09 2024-07-09 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2024-07-09 2024-07-09 iso4217:USD shares iso4217:USD shares false 0001712762 8-K 2024-07-09 bioAffinity Technologies, Inc. DE 001-41463 46-5211056 22211 W Interstate 10 Suite 1206 San Antonio TX 78257 (210) 698-5334 false false false false Common Stock, par value $0.007 per share BIAF NASDAQ Tradeable Warrants to purchase Common Stock BIAFW NASDAQ true false